Abstract
The cryoprecipitate is an essential blood product as they are rich in factor VIII, fibrinogen, von Willebrand factor, factor XIII, and fibronectin, and their volume is too small. They play a significant role in the management of massive transfusion nowadays. Usually, they are used without ABO group consideration. We here report a case in which immunohematological problems arose due to out-of-group transfusion of cryoprecipitate. We suggest that the possibility of incompatibility subsequently is to be kept in mind during transfusion of large quantity cryoprecipitate, and ABO group compatible may be preferred.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
